In an 83-year-old woman with osteoporosis, which medication (other than calcium) and what dose should be given to strengthen bone?

Recommended Treatment for 83-Year-Old Woman with Osteoporosis

Start with a bisphosphonate as first-line therapy: alendronate 70 mg orally once weekly OR zoledronic acid 5 mg intravenously once yearly. 1

Primary Treatment Recommendation

The 2023 American College of Physicians guideline provides the strongest and most recent evidence supporting bisphosphonates as initial pharmacologic treatment for postmenopausal women with osteoporosis 1. This recommendation is based on:

• Most favorable benefit-to-harm ratio among all osteoporosis medications
• Proven fracture reduction across vertebral, hip, and nonvertebral sites
• Cost-effectiveness with widely available generic formulations
• High-certainty evidence for efficacy

Specific Dosing Options:

Oral bisphosphonates:

• Alendronate 70 mg once weekly (most commonly used)
• Risedronate 35 mg once weekly (alternative)

Intravenous bisphosphonate:

• Zoledronic acid 5 mg once yearly (preferred if adherence concerns, GI intolerance, or difficulty with oral administration) 2

At age 83, zoledronic acid may be particularly advantageous given the low adherence rates (~30% at 1 year) with oral bisphosphonates 2. The annual IV infusion eliminates daily/weekly dosing requirements and ensures medication delivery.

Alternative Treatment: Denosumab

If bisphosphonates are contraindicated or not tolerated, use denosumab 60 mg subcutaneously every 6 months 2.

Denosumab demonstrates:

• 68% reduction in vertebral fractures
• 39% reduction in hip fractures
• 19% reduction in nonvertebral fractures 2

Critical Denosumab Warning:

Never stop denosumab abruptly without transitioning to another antiresorptive therapy (bisphosphonate, hormone therapy, or SERM). Discontinuation causes rapid bone loss and rebound increase in fracture risk, including risk of multiple vertebral fractures 2. This is a major disadvantage compared to bisphosphonates, which have residual skeletal effects after discontinuation.

Very High-Risk Patients

If this 83-year-old woman has severe or multiple vertebral fractures, she qualifies as "very high risk" and should receive:

Teriparatide 20 mcg subcutaneously daily OR abaloparatide 80 mcg subcutaneously daily for up to 2 years 2

Followed by mandatory transition to bisphosphonate or denosumab to maintain bone density gains 2. Anabolic agents alone without subsequent antiresorptive therapy will result in rapid bone loss.

Essential Adjunctive Therapy

All patients must receive adequate calcium and vitamin D supplementation 1, 2:

• Vitamin D: 700-800 IU daily minimum (target serum 25(OH)D ≥75 nmol/L) 3
• Calcium: 1000-1200 mg daily (preferably from diet)

This is non-negotiable as virtually all osteoporosis drug trials included calcium and vitamin D supplementation, meaning proven efficacy requires these supplements 2.

Treatment Duration and Monitoring

Bisphosphonates:

• Reassess fracture risk after 3-5 years 2
• Consider "drug holiday" (temporary discontinuation up to 5 years) if patient transitions to low-moderate risk 2
• Continue therapy if high fracture risk persists 2
• Shorter reassessment at 3 years for zoledronic acid given annual dosing 2

Denosumab:

• Reassess after 5-10 years 2
• No drug holidays permitted due to rapid offset and rebound risk 2

Key Safety Considerations

Rare but Serious Adverse Events (All Treatments):

• Osteonecrosis of the jaw (ONJ): Extremely rare; risk increases with longer duration (>5 years) 1, 2
• Atypical femoral fractures (AFF): Extremely rare; treating 1000 women for 3 years causes 0.08 AFF while preventing 100 fractures including 11 hip fractures 2

The benefits overwhelmingly outweigh these rare harms for up to 5 years of treatment 2.

Bisphosphonate-Specific Precautions:

• Renal function: Avoid if eGFR <35 mL/min for alendronate and zoledronic acid 2
• Zoledronic acid: Ensure adequate hydration and minimum 15-minute infusion time to prevent renal damage 2
• Oral bisphosphonates: Take on empty stomach with full glass of water; remain upright 30-60 minutes to prevent esophageal irritation

At Age 83:

• Assess fall risk and implement fall prevention strategies
• Review polypharmacy for drug interactions increasing fall/fracture risk 1
• Ensure adequate renal function before bisphosphonate initiation

Clinical Algorithm Summary

1. First-line: Bisphosphonate (alendronate 70 mg weekly OR zoledronic acid 5 mg yearly) 1
2. If bisphosphonate contraindicated/intolerant: Denosumab 60 mg every 6 months 2
3. If very high risk (severe/multiple vertebral fractures): Anabolic agent for 1-2 years → transition to bisphosphonate 2
4. Always add: Vitamin D 700-800 IU daily + calcium 1000-1200 mg daily 2, 3
5. Reassess: 3-5 years for bisphosphonates; 5-10 years for denosumab 2